Ultragenyx Pharmaceutical (NASDAQ:RARE) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.25 by 12 Brokerage Firm. 10 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 1 Brokerage Firms have advised hold.
Other Equity analysts have also commented on the company shares. JMP Securities maintains its view on Ultragenyx Pharmaceutical (NASDAQ:RARE) according to the research report released by the firm to its investors. The shares have now been rated Market Outperform by the stock experts at the ratings house. JMP Securities raises the price target from $80 per share to $84 per share on Ultragenyx Pharmaceutical . The rating by the firm was issued on June 8, 2016.
Ultragenyx Pharmaceutical (NASDAQ:RARE) should head towards $99.64 per share according to 11 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $84 per share. The higher price estimate target is at $125 according to the Analysts.
Ultragenyx Pharmaceutical (NASDAQ:RARE) witnessed a decline in the market cap on Tuesday as its shares dropped 4.53% or 2.47 points. After the session commenced at $54.86, the stock reached the higher end at $54.86 while it hit a low of $51.14. With the volume soaring to 1,099,151 shares, the last trade was called at $52.03. The company has a 52-week high of $137.05. The company has a market cap of $2,030 million and there are 39,020,576 shares in outstanding. The 52-week low of the share price is $49.
Ultragenyx Pharmaceutical Inc. has lost 14.7% in the last five trading days and dropped 18.72% in the last 4 weeks. Ultragenyx Pharmaceutical Inc. has dropped 16.65% during the last 3-month period . Year-to-Date the stock performance stands at -53.62%.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).